Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 2171-2180 of 10980

Edit search filters
  1. HEMORRHOIDAL EMBOLIZATION TRIAL

    Rochester, MN

  2. Workplace-Focused Wellness and Exercise Initiative on Employee Perceived Wellness and Workplace Satisfaction.

    Jacksonville, FL

  3. A Study Of The Drugs Selumetinib Vs. Carboplatin And Vincristine In Patients With Low-Grade Glioma

    Rochester, MN

  4. A Study of Rilvegostomig Plus Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  5. A Study to Evaluate Durvalumab plus Topotecan or Lurbinectedin in Patients with Small Cell Lung Cancer

    Rochester, MN

  6. Study Of JK07 In Patients With Chronic Heart Failure

    Rochester, MN

  7. A Study of CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  8. Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. A Study Of 177Lu-FAP-2286 In Advanced Solid Tumors

    Rochester, MN, Jacksonville, FL

  10. The ENCIRCLE Trial

    Rochester, MN

.

Mayo Clinic Footer